Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Encinitas, Califfornia--(Newsfile Corp. - August 7, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today reported financial results for the second quarter ended June 30, 2026, and provided an update on its clinical pipeline of small-molecule therapies for retinal diseases and its corporate development activities.

Second Quarter 2026 and Recent Highlights * Advanced enrollment in the Phase 2 ABACUS-2 clinical trial of KIO-301 into the higher-dose cohort * Continued enrollment in the higher-dose cohort of the Phase 2 KLARITY clinical trial of KIO-104 * Ended the quarter with approximately $16.8 million in cash and short-term investments, providing an expected operating runway into late 2028 * Secured a private placement for up to $24.0 million in gross proceeds, including $5.0 million received upfront, with the remaining proceeds contingent on the exercise of near-term milestone-based warrants